☆ 4.4 Article

Cost-effectiveness analyses of natalizumab (Tysabri (R)) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK

PHARMACOECONOMICS (2008)

Related references

Note: Only part of the references are listed.

Article Clinical Neurology

Randomized, comparative study of interferon β-1a treatment regimens in MS -: The EVIDENCE trial

H Panitch et al.

NEUROLOGY (2002)

Add to Collection

© Peeref 2019-2024. All rights reserved.